Patents by Inventor Priti Kumar
Priti Kumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108679Abstract: This invention discloses composition and manufacturing processes of a toxicity free botanical drug formulation for relief from breathing difficulties. This botanical drug is manufactured from plants Syzygium aromaticum or component(s) thereof, plant Elettaria cardamomum or component(s) thereof and sweeteners or component(s) thereof. This botanical drug was administered to human volunteers by buccal, supralingual, sublingual and oral routes in effective amount for an effective time-period. Effective amount and effective time of administration varies from one human volunteer to another depending upon type and severity of breathing difficulties.Type: ApplicationFiled: October 1, 2022Publication date: April 4, 2024Inventors: ASHOK KUMAR, PRAKRATI CHIRAG ACHARYA, PRITI KUMAR, ADITI KUMAR
-
Patent number: 11097073Abstract: A nose-to-brain drug delivery device is provided. The nose-to-brain drug delivery device includes a freeze-dried drug container for storing a freeze-dried drug, a restoring solvent container for storing a solvent for thawing the freeze-dried drug, a membrane for preventing the freeze-dried drug from being mixed with the solvent, and a compressor for providing a driving force. The membrane is opened by the driving force of the compressor to mix the freeze-dried drug with the solvent, thereby thawing the freeze-dried drug, and the thawed drug is sprayed by the driving force of the compressor.Type: GrantFiled: November 16, 2018Date of Patent: August 24, 2021Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)Inventors: Sang-Kyung Lee, Kun Ho Chung, Irfan Ullah, Priti Kumar, Sangah Lee
-
Patent number: 11000355Abstract: A test device is disclosed. The test device includes a supporter providing a seating surface for an experimental animal, and a chair formed on the supporter and configured to induce a drug inhalation posture in which a head of the experimental animal is directed downward. Thus, a mecca position may be induced by a simple operation of seating an unconscious experimental animal on the chair. As a result, nose-to-brain drug delivery may be performed.Type: GrantFiled: December 6, 2016Date of Patent: May 11, 2021Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)Inventors: Sang-Kyung Lee, Irfan Ullah, Kunho Chung, Sangah Lee, Priti Kumar
-
Patent number: 10772827Abstract: The present invention relates to a nasal administration composition for preventing or treating ischemic cerebrovascular disease, containing a Fas targeting peptide (FTP). When using the pharmaceutical composition or kit of the present invention, a drug can be effectively delivered to brain tissue and the ischemic cerebrovascular disease of a subject can be effectively prevented or treated.Type: GrantFiled: November 14, 2016Date of Patent: September 15, 2020Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITYInventors: Sang-Kyung Lee, Irfan Ullah, Kun Ho Chung, Jung Ju Oh, Min Hyung Lee, Priti Kumar
-
Publication number: 20190151573Abstract: A nose-to-brain drug delivery device is provided. The nose-to-brain drug delivery device includes a freeze-dried drug container for storing a freeze-dried drug, a restoring solvent container for storing a solvent for thawing the freeze-dried drug, a membrane for preventing the freeze-dried drug from being mixed with the solvent, and a compressor for providing a driving force. The membrane is opened by the driving force of the compressor to mix the freeze-dried drug with the solvent, thereby thawing the freeze-dried drug, and the thawed drug is sprayed by the driving force of the compressor.Type: ApplicationFiled: November 16, 2018Publication date: May 23, 2019Applicant: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)Inventors: Sang-Kyung LEE, Kun Ho CHUNG, Irfan ULLAH, Priti KUMAR, Sangah LEE
-
Publication number: 20180360583Abstract: A test device is disclosed. The test device includes a supporter providing a seating surface for an experimental animal, and a chair formed on the supporter and configured to induce a drug inhalation posture in which a head of the experimental animal is directed downward. Thus, a mecca position may be induced by a simple operation of seating an unconscious experimental animal on the chair. As a result, nose-to-brain drug delivery may be performed.Type: ApplicationFiled: December 6, 2016Publication date: December 20, 2018Inventors: Sang-Kyung LEE, Irfan ULLAH, Kunho CHUNG, Sangah LEE, Priti KUMAR
-
Publication number: 20180325811Abstract: The present invention relates to a nasal administration composition for preventing or treating ischemic cerebrovascular disease, containing a Fas targeting peptide (FTP). When using the pharmaceutical composition or kit of the present invention, a drug can be effectively delivered to brain tissue and the ischemic cerebrovascular disease of a subject can be effectively prevented or treated.Type: ApplicationFiled: November 14, 2016Publication date: November 15, 2018Inventors: Sang-Kyung LEE, Irfan ULLAH, Kun Ho CHUNG, Jung Ju OH, Min Hyung LEE, Priti KUMAR
-
Publication number: 20180028677Abstract: The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the compositions provided by the present invention to deliver agents, for example therapeutic agents for the treatment of neurologically related disorders.Type: ApplicationFiled: June 30, 2017Publication date: February 1, 2018Applicant: Children's Medical Center CorporationInventors: Manjunath NARASIMHASWAMY, Premlata SHANKAR, Priti KUMAR
-
Patent number: 9757470Abstract: The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the compositions provided by the present invention to deliver agents, for example therapeutic agents for the treatment of neurologically related disorders.Type: GrantFiled: April 30, 2014Date of Patent: September 12, 2017Assignee: Children's Medical Center CorporationInventors: Manjunath Narasimhaswamy, Premlata Shankar, Priti Kumar
-
Patent number: 9683042Abstract: The present invention relates to a humanized scFv delivery vehicle targeted to be human T-cell specific, and provides: a humanized scFv which comprises a heavy-chain variable region (VH) consisting of a polypeptide comprising an amino acid sequence given by sequence number 32 and comprises a light-chain variable region (VL) consisting of a polypeptide comprising an amino acid sequence given by sequence number 34; and a T-cell-specific drug or marker delivery vehicle comprising the humanized scFv. The humanized scFv of the present invention has minimalised antigenicity and has an effect which does not give rise to an immune reaction even when used in the human body, and thus can advantageously be used as a delivery vehicle for specifically delivering a target substance such as a siRNA gene or an immune reaction regulating protein to T-cells.Type: GrantFiled: March 5, 2013Date of Patent: June 20, 2017Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, HANYANG UNIVERSITYInventors: Sang Kyung Lee, Hyo Jeong Hong, Priti Kumar
-
Publication number: 20160060341Abstract: The present invention relates to a humanized scFv delivery vehicle targeted to be human T-cell specific, and provides: a humanized scFv which comprises a heavy-chain variable region (VH) consisting of a polypeptide comprising an amino acid sequence given by sequence number 32 and comprises a light-chain variable region (VL) consisting of a polypeptide comprising an amino acid sequence given by sequence number 34; and a T-cell-specific drug or marker delivery vehicle comprising the humanized scFv. The humanized scFv of the present invention has minimalised antigenicity and has an effect which does not give rise to an immune reaction even when used in the human body, and thus can advantageously be used as a delivery vehicle for specifically delivering a target substance such as a siRNA gene or an immune reaction regulating protein to T-cells.Type: ApplicationFiled: March 5, 2013Publication date: March 3, 2016Inventors: Sang Kyung LEE, Hyo Jeong HONG, Priti KUMAR
-
Publication number: 20140294727Abstract: The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the compositions provided by the present invention to deliver agents, for example therapeutic agents for the treatment of neurologically related disorders.Type: ApplicationFiled: April 30, 2014Publication date: October 2, 2014Applicant: Children's Medical Center CorporationInventors: Manjunath NARASIMHASWAMY, Premlata Shankar, Priti Kumar
-
Patent number: 8772471Abstract: The present invention provides a method of delivering RNA interference molecules to a cell or a cell in a subject, which comprises contacting the cell with a protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a protein, the protein comprising (1) a targeting moiety, which will specifically bind to a site on a target cell, and (2) a binding moiety linked thereto, which will bind to the double stranded RNA, wherein the double stranded RNA segment is delivered to a cell and effects RNA interference of the target RNA in the cell.Type: GrantFiled: January 25, 2008Date of Patent: July 8, 2014Assignees: Industry-University Cooperation Foundation Hanyang University, Immune Disease InstituteInventors: Premlata Shankar, Sang-Kyung Lee, Manjunath Narasimhaswamy, Priti Kumar, Haoquan Wu, Hong-Seok Ban
-
Patent number: 8748567Abstract: The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the compositions provided by the present invention to deliver agents, for example therapeutic agents for the treatment of neurologically related disorders.Type: GrantFiled: May 22, 2007Date of Patent: June 10, 2014Assignee: Children's Medical Center CorporationInventors: Manjunath Narasimhaswamy, Premlata Shankar, Priti Kumar
-
Patent number: 8668938Abstract: This invention discloses composition and manufacturing processes of a toxicity free botanical drug formulation for curative treatment of chronic diseases. It is manufactured from plants Crinum asiaticum and Crocus sativus. This drug was administered to human volunteers by oral and intranasal routes in effective amount for an effective time period. Effective amount and effective time of administration varies from one human volunteer to another depending upon age, body weight, length of disease, severity of disease, type of the disease. In vitro experiments show that this botanical drug causes proliferation and differentiation of stem cells.Type: GrantFiled: January 29, 2010Date of Patent: March 11, 2014Assignee: Ashok KumarInventors: Ashok Kumar, Aditi Kumar, Prakrati Kumar, Priti Kumar
-
Publication number: 20130028993Abstract: This invention discloses composition and manufacturing processes of a toxicity free botanical drug formulation for curative treatment of chronic diseases. It is manufactured from plants Crinum asiaticum and Crocus sativus. This drug was administered to human volunteers by oral and intranasal routes in effective amount for an effective time period. Effective amount and effective time of administration varies from one human volunteer to another depending upon age, body weight, length of disease, severity of disease, type of the disease. In vitro experiments show that this botanical drug causes proliferation and differentiation of stem cells.Type: ApplicationFiled: January 29, 2010Publication date: January 31, 2013Applicant: ASHOK KUMARInventors: Ashok Kumar, Aditi Kumar, Prakrati Kumar, Priti Kumar
-
Publication number: 20100233084Abstract: The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the compositions provided by the present invention to deliver agents, for example therapeutic agents for the treatment of neurologically related disorders.Type: ApplicationFiled: May 22, 2007Publication date: September 16, 2010Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Manjunath Narasimhaswamy, Premlata Shankar, Priti Kumar
-
Publication number: 20100209440Abstract: The present invention provides a method of delivering RNA interference molecules to a cell or a cell in a subject, which comprises contacting the cell with a protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a protein, the protein comprising (1) a targeting moiety, which will specifically bind to a site on a target cell, and (2) a binding moiety linked thereto, which will bind to the double stranded RNA, wherein the double stranded RNA segment is delivered to a cell and effects RNA interference of the target RNA in the cell.Type: ApplicationFiled: January 25, 2008Publication date: August 19, 2010Applicants: Immune Disease Institute, Inc., Industry-University Cooperation Foundation Hanyang University (IUCF-HYU)Inventors: Premlata Shankar, Sang-Kyung Lee, Manjunath Narasimhaswamy, Priti Kumar, Haoquan Wu, Hong-Seok Ban
-
Publication number: 20090047338Abstract: The present invention is directed to methods of treating flavivirus mediated diseases using siRNAs. The invention is based upon our findings in a mouse model that siRNAs directed against sequences conserved among multiple flaviviruses prevents and treats flavivirus infections. Accordingly, the present invention provides an isolated siRNA comprising a sense RNA and an antisense RNA strand or a single strand. The sense and the antisense RNA strands, or the single RNA strand, form an RNA duplex, and wherein the RNA strand comprises a nucleotide sequence identical to a target sequence of about 15 to about 30 contiguous nucleotides in flavivirus mRNA or mutant or variant thereof.Type: ApplicationFiled: October 5, 2006Publication date: February 19, 2009Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Manjunath N. Swamy, Premlata Shankar, Priti Kumar, Sang-Kyung Lee